Anthropic introduced Claude Science on Tuesday, a dedicated AI workbench designed to give scientists a unified environment for computational research, eliminating the need to constantly switch between databases, pipelines, and tools. The launch, announced at an AI for Science briefing, marks Anthropic's bet that workflow-level products, rather than just raw model capability, will drive its next phase of growth. The company is increasingly positioning itself as more than a model provider, aiming to own the operating layer for specific industries, much the way Claude Code has become the operating layer for software development.
What Claude Science Does
Claude Science is not a new AI model. Anthropic is explicit on this point: "It runs the same Claude models already available to everyone today (including Claude Opus 4.8), with no special access and no gating." Instead, the workbench is a purpose-built environment that connects to more than 60 scientific databases and comes preloaded with toolkits for genomics, protein structure analysis, and chemistry.
At the center of the system is a main AI assistant that acts as a project manager for scientists. It can organize entire research projects, connect to relevant databases, and delegate tasks to sub-assistants, essentially splitting work the way a principal investigator would hand off specialized tasks to team members.
Users can also create custom "expert" assistants tailored to their own research needs. A separate fact-checker AI double-checks citations and calculations before anything goes to publication. The reproducibility feature is particularly notable: Claude Science can generate figures, including 3D protein structures and chemistry diagrams, alongside the code that produced them.
Each figure includes "the exact code and environment that produced it, a plain-language description of how it was created, and the full message history," according to the company. Researchers can also edit figures in plain language, prompting the agent to update its underlying code automatically.
Built for the Lab, Not Just the Cloud
Claude Science can run on a lab's own infrastructure rather than sending data to Anthropic's servers, a meaningful feature for institutions handling sensitive or proprietary research data.
Early users are already reporting significant time savings. Allen Institute neuroscientist Jérôme Lecoq used the tool to build a multi-agent computational review pipeline. At the UCSF Brain Tumor Center, Stephen Francis's group relied on Claude Science to accelerate germline analysis of glioma, compressing a process that previously took considerably longer into a fraction of the time, with results independently validated.
A Shot at $30,000 in Credits
Claude Science is available in beta to anyone on Pro, Max, Team, and Enterprise subscriptions. Anthropic is also supporting up to 50 projects with up to $30,000 in credits.
"We are looking for postdoctoral and graduate projects that span domains and explore the boundaries of science, with an early focus on fields across biomedical research," the company said. Applications are open through July 15, 2026, with award notifications sent out by July 31.
Funded projects will run from September 1 to December 1, 2026.
The Competitive market
Claude Science enters a rapidly heating market for AI-powered scientific research tools. The launch comes just months after OpenAI released GPT-Rosalind in April, a specialized model fine-tuned for biological reasoning, available as a research preview limited to qualified enterprise customers in the U.S. OpenAI's early partners include Amgen, the Allen Institute, Moderna, Thermo Fisher, and Novo Nordisk.
Google DeepMind is playing a different game entirely, owning foundational science models like AlphaFold and AlphaGenome that competitors can only call into as tools. Its Gemini for Science platform bundles those models with more than 30 life science databases.
The result is three distinct distribution strategies competing for the same scientific research market: Anthropic is going wide with broad subscription access; OpenAI is going narrow and enterprise-gated; and Google is leaning on proprietary models no one else has. How this plays out could signal how AI vendors will compete in other specialized verticals like law, finance, and engineering.
Pharma as a Key Target
The pharma industry is clearly in Anthropic's sights. The company named Novo Nordisk and the Allen Institute as customer case studies, and the biomedical focus of the credits program highlights the push.
Claude Science builds on Anthropic's October 2025 launch of Claude for Life Sciences, which improved the Claude chatbot for life sciences tasks. The new workbench goes a step further, giving researchers a dedicated environment rather than a chatbot augmentation. For pharmaceutical companies racing to accelerate drug discovery and clinical research, Claude Science offers a way to centralize computational work that has historically been scattered across disparate platforms, potentially cutting months off research timelines.
